Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

StatusActive, Not Recruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Jul 2026 to Jun 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 35 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description revised
    • Collaborators: details revised at 1 of 1 entry
  2. Study completion date: Jan 21, 2026 to Jul 2026v32
  3. 2 versions Re-verified since May 21, 2025, no change to tracked fieldsv30-v31
  4. Results first posted: May 4, 2025
    • Enrollment target: 124 to 120
    • Secondary endpoint revised
    v29
  5. Re-verified, no change to tracked fieldsv28
Show 26 earlier versionsHide 26 earlier versions
  1. Study completion date: Jan 21, 2025 to Jan 21, 2026v27
  2. Study completion date: Jan 21, 2024 to Jan 21, 2025v26
  3. Primary and study completion dates: Jan 2024 to Jan 21, 2024v25
  4. Re-verified, no change to tracked fieldsv24
  5. Primary completion date: Nov 2022 to Jan 2024
    • Study completion date: Nov 2023 to Jan 2024
    v23
  6. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 100 to confirmed 124
    • Site details revised
    v22
  7. 3 versions Re-verified since Mar 2, 2021, no change to tracked fieldsv19-v21
  8. Start date: Feb 24, 2016 to Mar 22, 2016v18
  9. Primary completion date: Nov 2020 to Nov 2022
    • Study completion date: Nov 2022 to Nov 2023
    v17
  10. Primary completion date: Nov 2019 to Nov 2020
    • Study completion date: Nov 2020 to Nov 2022
    v16
  11. Eligibility criteria expanded, about 36 wordsv15
  12. 3 versions Re-verified since Oct 2, 2018, no change to tracked fieldsv12-v14
  13. Primary completion date: Nov 2018 to Nov 2019
    • Study completion date: Nov 2019 to Nov 2020
    v11
  14. Re-verified, no change to tracked fieldsv10
  15. Site contact updatedv9
  16. Study completion date: Nov 2018 to Nov 2019
    • Eligibility criteria expanded, about 179 words
    v8
  17. Primary and study completion dates: Nov 2017 to Nov 2018
    • Start date: Feb 2016 to Feb 24, 2016
    v7
  18. Eligibility criteria expanded, about 165 words
    • Site contact updated
    v6
  19. Study completion date: Nov 2017v5
  20. Site contact updatedv4
  21. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    • Eligibility criteria expanded, about 1 word
    v3
  22. Start date: Jan 2016 to Feb 2016v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to see whether the combination of two drugs called pembrolizumab and vorinostat can help people with advanced lung cancer. Researchers also want to find out if the combination of pembrolizumab and vorinostat is safe and tolerable. This study will compare the effects of the combination of two drugs called pembrolizumab and vorinostat with the effects of pembrolizumab alone. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for use to treat a deadly skin cancer called melanoma and lung cancer and vorinostat to treat some forms of blood and lymph node cancers.
Trial Details
NCT Number NCT02638090
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Lung Cancer, Non-small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov